Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1991 2
1995 1
1998 2
2001 3
2002 1
2003 1
2004 1
2005 2
2006 1
2010 1
2012 1
2013 1
2014 3
2015 1
2016 3
2017 2
2018 3
2023 2
2024 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer.
Paller CJ, Wang L, Fu W, Kumar R, Durham JN, Azad NS, Laheru DA, Browner I, Kachhap SK, Boyapati K, Odeny T, Armstrong DK, Meyer CF, Gaillard S, Brahmer JR, Page I, Wang H, Diaz LA Jr. Paller CJ, et al. Cancer Res Commun. 2023 Feb 28;3(2):338-346. doi: 10.1158/2767-9764.CRC-23-0002. eCollection 2023 Feb. Cancer Res Commun. 2023. PMID: 36860652 Free PMC article. Clinical Trial.
PURPOSE: Mistletoe extract (ME) is widely used for patients with cancer to support therapy and to improve quality of life (QoL). ...SIGNIFICANCE: Although ME is widely used for cancers, its efficacy and safety are uncertain. This first phase I trial of int …
PURPOSE: Mistletoe extract (ME) is widely used for patients with cancer to support therapy and to improve quality of life (QoL …
Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series.
Zuzak TJ, Wasmuth A, Bernitzki S, Schwermer M, Längler A. Zuzak TJ, et al. Complement Ther Med. 2018 Oct;40:198-202. doi: 10.1016/j.ctim.2018.01.002. Epub 2018 Jan 11. Complement Ther Med. 2018. PMID: 30219449
Recent studies have shown direct positive effects on tumor reduction through Viscum album (mistletoe) extracts in adults, mainly as a result of higher dosage treatment and intravenous or intratumoral application. ...CONCLUSION: Our study underpinned the safety and f …
Recent studies have shown direct positive effects on tumor reduction through Viscum album (mistletoe) extracts in adults, mainly as a …
Intravenous Mistletoe Treatment in Integrative Cancer Care: A Qualitative Study Exploring the Procedures, Concepts, and Observations of Expert Doctors.
Kienle GS, Mussler M, Fuchs D, Kiene H. Kienle GS, et al. Evid Based Complement Alternat Med. 2016;2016:4628287. doi: 10.1155/2016/4628287. Epub 2016 Apr 24. Evid Based Complement Alternat Med. 2016. PMID: 27239209 Free PMC article.
Background. Mistletoe therapy (MT) is widely used in patient-centered integrative cancer care. The objective of this study was to explore the concepts, procedures, and observations of expert doctors, with a focus on intravenous MT. ...Conclusion. Individualiz …
Background. Mistletoe therapy (MT) is widely used in patient-centered integrative cancer care. The objective of this study was …
Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study.
Steele ML, Axtner J, Happe A, Kröz M, Matthes H, Schad F. Steele ML, et al. Evid Based Complement Alternat Med. 2014;2014:236310. doi: 10.1155/2014/236310. Epub 2014 May 15. Evid Based Complement Alternat Med. 2014. PMID: 24955100 Free PMC article.
Results. Of 475 cancer patients who received intravenous infusions of Helixor, Abnoba viscum, or Iscador mistletoe preparations, 22 patients (4.6%) reported 32 ADRs of mild (59.4%) or moderate severity (40.6%). ...Overall, patients were almost two times less …
Results. Of 475 cancer patients who received intravenous infusions of Helixor, Abnoba viscum, or Iscador mistletoe prep …
Pharmakokinetics of Mistletoe Lectins after Intravenous Application of a Mistletoe Product in Healthy Subjects.
Lederer AK, Rieger S, Schink M, Huber R. Lederer AK, et al. Pharmaceuticals (Basel). 2024 Feb 22;17(3):278. doi: 10.3390/ph17030278. Pharmaceuticals (Basel). 2024. PMID: 38543063 Free PMC article.
Mistletoe lectins (ML) have cytotoxic and immunomodulating properties, and subcutaneously applied mistletoe products (MP) containing ML have approval for supportive cancer treatment. MP are also given off-label intravenously, but data about pharmacokin …
Mistletoe lectins (ML) have cytotoxic and immunomodulating properties, and subcutaneously applied mistletoe products (MP) cont …
Fever Therapy With Intravenously Applied Mistletoe Extracts for Cancer Patients: A Retrospective Study.
Schläppi M, Ewald C, Kuehn JJ, Weinert T, Huber R. Schläppi M, et al. Integr Cancer Ther. 2017 Dec;16(4):479-484. doi: 10.1177/1534735416658121. Epub 2016 Jul 7. Integr Cancer Ther. 2017. PMID: 27387685 Free PMC article.
PURPOSE: So-called spontaneous remissions in cancer often seem to occur after febrile events. Mistletoe preparations (MPs) are used off-label intravenously to induce fever within concepts of integrative oncology. We wanted to investigate the frequency of febr …
PURPOSE: So-called spontaneous remissions in cancer often seem to occur after febrile events. Mistletoe preparations (MPs) are …
Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts.
Rostock M, Huber R, Greiner T, Fritz P, Scheer R, Schueler J, Fiebig HH. Rostock M, et al. Anticancer Res. 2005 May-Jun;25(3B):1969-75. Anticancer Res. 2005. PMID: 16158932 Free article.
-injected lectin-rich mistletoe extract at different dosages and i.t.-injected mistletoe lectin I in comparison to intravenous (i.v.) ...CONCLUSION: I.t.-injected lectin-rich mistletoe extract should be further evaluated in patients with inoperable loc …
-injected lectin-rich mistletoe extract at different dosages and i.t.-injected mistletoe lectin I in comparison to intraven …
Immune modulation using mistletoe (Viscum album L.) extracts Iscador.
Büssing A. Büssing A. Arzneimittelforschung. 2006 Jun;56(6A):508-15. doi: 10.1055/s-0031-1296818. Arzneimittelforschung. 2006. PMID: 16927532 Review.
One repeatedly finds that mistletoe (Viscum album L.) extracts show immune-modulating effects. This is also true in many cases in the experimental setting. ...However, patients with stronger local reaction showed a significant decrease of HLA-DR+ T cells as compared to pat …
One repeatedly finds that mistletoe (Viscum album L.) extracts show immune-modulating effects. This is also true in many cases in the …
Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Schad F, Atxner J, Buchwald D, Happe A, Popp S, Kröz M, Matthes H. Schad F, et al. Integr Cancer Ther. 2014 Jul;13(4):332-40. doi: 10.1177/1534735413513637. Epub 2013 Dec 19. Integr Cancer Ther. 2014. PMID: 24363283 Free article.
Here we report on 39 patients with advanced, inoperable pancreatic cancer, who received in total 223 intratumoral applications of mistletoe, endoscopic ultrasound guided or under transabdominal ultrasound control. ...Due to the multimodal therapeutic setting and the …
Here we report on 39 patients with advanced, inoperable pancreatic cancer, who received in total 223 intratumoral applications of …
Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.
Huber R, Schlodder D, Effertz C, Rieger S, Tröger W. Huber R, et al. BMC Complement Altern Med. 2017 Sep 18;17(1):465. doi: 10.1186/s12906-017-1971-1. BMC Complement Altern Med. 2017. PMID: 28923036 Free PMC article. Clinical Trial.
BACKGROUND: Mistletoe extracts have anti-tumor properties and are approved for subcutaneous use in cancer patients. Data on Intravenous application are limited. METHODS: An aqueous extract from pine-mistletoe was used to investigate maximum tolerable d …
BACKGROUND: Mistletoe extracts have anti-tumor properties and are approved for subcutaneous use in cancer patients. Data on …
31 results